(95 days)
Not Found
No
The device description and performance studies focus on the material properties and antimicrobial/hemostatic efficacy of the dressing, with no mention of AI or ML.
Yes
The device is a therapeutic device because its intended uses include absorbing exudate, covering and protecting catheter sites, and controlling surface bleeding. It also contains an antimicrobial agent to protect against microbial colonization and has hemostatic properties, all of which are direct actions to treat or manage a condition.
No
This device is a wound dressing designed to absorb exudate, protect catheter sites, control surface bleeding, and provide antimicrobial properties. It does not perform any diagnostic functions.
No
The device description clearly indicates it is a physical dressing made of polyurethane sponge impregnated with chemical agents (CHG and m.doc™). It is a tangible, sterile product intended for physical application to a wound site.
Based on the provided information, the HemCon GuardIVa® Antimicrobial Hemostatic IV Dressing is not an In Vitro Diagnostic (IVD).
Here's why:
- Intended Use: The intended use clearly states it's a wound dressing for absorbing exudate, covering and protecting catheter sites, and controlling surface bleeding. These are all applications directly on or around the patient's body.
- Device Description: The description details a physical dressing with impregnated substances (CHG and m.doc™) that act on the wound site.
- Lack of In Vitro Testing for Diagnosis: The performance studies focus on biocompatibility, wound healing, hemostasis, skin flora suppression, and antimicrobial efficacy of the dressing itself. There are no mentions of testing patient samples (blood, urine, tissue, etc.) to diagnose a condition or provide information about a patient's health status.
- No Mention of Analyzing Samples: The device does not collect, process, or analyze biological samples from the patient for diagnostic purposes.
In Vitro Diagnostics (IVDs) are medical devices intended to be used in vitro for the examination of specimens derived from the human body in order to provide information for diagnostic, monitoring or compatibility purposes. This device does not fit that definition.
N/A
Intended Use / Indications for Use
The HemCon® GuardIVa® Antimicrobial Hemostatic IV Dressing is intended for use as a hydrophilic wound dressing to absorb exudate, cover and protect catheter sites. Common applications include IV catheters, other intravenous catheters and percutaneous devices. It is also indicated for control of surface bleeding from percutaneous catheters and vascular access sites.
Product codes
QSY, FRO
Device Description
The HemCon® GuardIVa® Antimicrobial Hemostatic IV Dressing is a sterile hydrophilic, absorptive polyurethane sponge dressing impregnated with the broad spectrum antimicrobial agent chlorhexidine gluconate (CHG) and HemCon's proprietary hemostatic agent, microdispersed oxidized cellulose (m.doc™). The dressing is backed with a non-stick polyurethane film and is individually packaged in a peelable low density polyethylene (LDPE) and Tyvek® pouch. The dressing is provided both sterile. The sterile version of the dressing is terminally sterilized with gamma irradiation to a sterility assurance level (SAL) of 10-6.
The hemostatic properties of m.doc™ enhances the ability of the foam to control surface bleeding from percutaneous catheters and vascular access sites.
CHG is a well known antiseptic agent with broad spectrum antimicrobial and antifungal activity against a wide range of gram positive and gram negative organisms yeast and fungi (See Table 1). The CHG antimicrobial agent protects the dressing from microbial colonization.
GuardIVa® is an adjunct to infection control measures by providing sustained IV site protection, GuardIVa® has not been clinically tested for its ability to reduce catheter related blood stream infections (CR-BSI).
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Catheter sites, IV catheters, other intravenous catheters and percutaneous devices, percutaneous catheters and vascular access sites.
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Biocompatibility: Biocompatibility has been demonstrated per ISO 10993. Categorization of the device by nature of body contact deduces the GuardIVa® Antimicrobial Hemostatic IV Dressing is a surface-contacting device that contacts breached or compromised surfaces. The duration of contact may be prolonged at more than 24 hours, but no more than 30 days. Cytotoxicity, irritation and sensitization testing was performed by contract testing laboratories under GLP conditions per standard protocols.
In Vivo Efficacy - Dermal Wound Healing Studies: Two independent in vivo dermal wound healing studies in rats were performed by contract testing laboratories under GLP conditions to demonstrate that the CHG in GuardIVa® does not adversely affect the rate of wound healing compared to un-treated wounds. Wounds treated with GuardIVa® healed at a rate comparable to untreated wounds with no visible signs of erythema and with an edema response comparable to that of un-treated wounds. Another commercially available CHG containing sponge dressing was used as a control and it did have a pronounced adverse effect on healing and edema.
In Vivo Efficacy - Hemostatic Properties of GuardIVa®: The haemostatic efficacy of GuardIVa® Antimicrobial Hemostatic IV Dressing was tested in comparison to standard gauze dressing in a rabbit ear model. The time to hemostasis was significantly reduced in wounds treated with GuardIVa® (48 s) compared to standard gauze (113 s). Furthermore, up to seven times less blood loss was observed for wounds treated with GuardIVa® (0.17 g) compared with standard gauze (1.30 g).
In Vivo Efficacy - Suppression of Skin Flora Re-growth in Healthy Volunteers: A study, conducted independently by the Centre for Laboratory Activities in Public Health Protection and Promotion, National Reference Laboratory for Disinfection and Sterilization, National Institute of Health, Prague, Czech Republic, on healthy human volunteers, demonstrated the ability of GuardIVa® to suppress skin flora re-growth for up to 10 days, maintaining skin flora at a level equivalent to that observed immediately following preoperative skin preparation (70% isopropy) alcohol solution).
Sustained Antimicrobial Efficacy - 7 Day Log Reduction Values: The sustained antimicrobial efficacy of GuardIVa® Antimicrobial Hemostatic IV Dressing, for up to 7 days, was demonstrated in vitro using a modified version of the AATCC Test Method 100-2004 "Assessment of Antibacterial Finishes on Textiles". GuardIVa® dressings were tested in triplicate against seven [7] bacterial strains, S. aureus (MRSA), S. epidermidis (MRSE), E. faecium (VRE), P. aeruginosa, A. baumanii, K. pneumoniae and E. coli, the diploid yeast C. albicans and the fungus A. niger. A greater than 4 log reduction in microbial count was observed for all test organisms.
Antimicrobial Efficacy - Zone of Inhibition Measurements: Kirby-Bauer Zone of (nhibition (Zol) measurements were used to demonstrate the bactericidal or bacteriostatic properties of GuardIVa® Antimicrobial Hemostatic IV Dressing aqainst a range of micro-organisms over a 7 day period (See Table 3). Individual test articles were placed onto agar plates and incubated for 24 hr at 35 - 37°C. The area under the test articles was swabbed and the swab was transferred onto sterile agar plates. The test articles were then placed on a freshly inoculated agar plates and the procedure repeated for 7 days. Growth from the swabs taken from the test articles indicated bacteriostatic action (slowed growth over 7 days) of the CHG in GuardIVa®, while no growth over 7 days indicated bactericidal action. GuardIVa® Antimicrobial Hemostatic IV Dressing was shown to be bactericidal against five of the test organisms (MRSA, MRSE, VRE, E.coli and K. pneumoniae) and bacteriostatic against the other three organisms (P. aeruginosa, A. baumanii and C. albicans).
Sterility: A sterility validation for GuardIVa® Antimicrobial Hemostatic IV Dressing was completed following ISO 11137:2006 requirements to demonstrate a 10-6 SAL using the VDma25 method.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
N/A
0
Image /page/0/Picture/0 description: The image contains the logos of the U.S. Department of Health & Human Services and the U.S. Food & Drug Administration (FDA). The Department of Health & Human Services logo is on the left, featuring a stylized human figure. To the right is the FDA logo, with the letters "FDA" in a blue square and the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.
HemCon Medical Technologies Europe Limited Barbara McGrath Manager of Regulatory Affairs 10575 SW Cascade Avenue, Suite 130 Portland, Oregon 97223-4363
April 21, 2023
Re: K121485
Trade/Device Name: GuardIVa® Antimicrobial Hemostatic IV Dressing Regulatory Class: Unclassified Product Code: QSY
Dear Barbara McGrath:
The Food and Drug Administration (FDA) is sending this letter to notify you of an administrative change related to your previous substantial equivalence (SE) determination letter dated August 21, 2012. Specifically, FDA is updating this SE Letter because FDA has better categorized your device technology under product code QSY.
Please note that the 510(k) submission was not re-reviewed. For questions regarding this letter please contact Julie Morabito, OHT4: Office of Surgical and Infection Control Devices, 240-402-3839, Julie.Morabito@fda.hhs.gov.
Sincerely,
Julie A. Morabito -S
Julie Morabito, Ph.D. Assistant Director DHT4B: Division of Infection Control and Plastic Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
1
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with three tail feathers. The eagle is enclosed in a circle with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
HemCon Medical Technologies Europe Limited % HemCon Medical Technologies, Incorporated Ms. Barbara McGrath Manager of Regulatory Affairs 10575 SW Cascade Avenue, Suite 130 Portland. Oregon 97223
AUG 2 1 2012
Re: K121485
Trade/Device Name: GuardIVa® Antimicrobial Hemostatic IV Dressing Regulatory Class: Unclassified Product Code: FRO Dated: July 18, 2012 Received: July 19, 2012
Dear Ms. McGrath:
We have reviewed your Section 510(k) premarket notification of intent to market the device . referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
2
Page 2 - Ms. Barbara McGrath
forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Sincerely yours,
Mark N. Melkerson
Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health .
Enclosure
3
K121485-
Page 1 of 1
Indications for Use Statement
Applicant: HemCon Medical Technologies Europe Ltd.
510(k) Number: K121485
Device Name: GuardIVa® Antimicrobial Hemostatic IV Dressing
Indications for Use (Rx):
The HemCon GuardIVa® Antimicrobial Hemostatic IV Dressing is intended for use as a hydrophilic wound dressing to absorb exudate, cover and protect catheter sites. Common applications include IV catheters, other intravenous catheters and percutaneous devices. It is also indicated for control of surface bleeding from percutaneous catheters and vascular access sites.
Prescription Use X (Part 21 CFR 801 Subpart D) . AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(Please Do Not Write Below This Line - Continue On Another Page If Needed)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Daniel Knoerker MM
(Division Sign Off)
(Division Sign-Off) Division of Surgical, Orthopedic, and Restorative Devices
510(k) Number K121455
4
Hem Con Medical Technologies Europe Ltd.. 6 Courtyard Business Centre, Orchard Lane, Blackrock, Co. Dublin, (teland
TEL: +353 (0) 1 2064727 FAX: +1 (503) 245-1326 EMAIL: info@hemcan.com
510(k) Summary
AUG 2 1 2012
In accordance with 21 CFR 807.92 the following summary of information is provided:
Trade Name: GuardIVa® Antimicrobial Hemostatic IV Dressing Common Name: Wound Dressing Classification: Unclassified Classification Name: Dressing Product Code: FRO Predicate Device(s): GuardIVa™ Antimicrobial Hemostatic IV Dressing (K093729) Company Name: HemCon Medical Technologies Europe Ltd. Company Address: 6 Courtyard Business Centre, Orchard Lane. Blackrock, Co. Dublin Ireland Contact Person: Barbara MªGrath Regulatory Affairs Manager Contact Phone: (503) 245.0459 x120 (503) 245.1326 Contact Fax:
Date of Preparation:
. 17 Aug 2012
Description of the Device:
The HemCon® GuardIVa® Antimicrobial Hemostatic IV Dressing is a sterile hydrophilic, absorptive polyurethane sponge dressing impregnated with the broad spectrum antimicrobial agent chlorhexidine gluconate (CHG) and HemCon's proprietary hemostatic agent, microdispersed oxidized cellulose (m.doc™). The dressing is backed with a non-stick polyurethane film and is individually packaged in a peelable low density polyethylene (LDPE) and Tyvek® pouch. The dressing is provided both sterile. The sterile version of the dressing is terminally sterilized with gamma irradiation to a sterility assurance level (SAL) of 10-°.
The hemostatic properties of m.doc™ enhances the ability of the foam to control surface bleeding from percutaneous catheters and vascular access sites.
CHG is a well known antiseptic agent with broad spectrum antimicrobial and antifungal activity against a wide range of gram positive and gram negative organisms yeast and fungi (See Table 1). The CHG antimicrobial agent protects the dressing from microbial colonization.
GuardIVa® is an adjunct to infection control measures by providing sustained IV site protection, GuardIVa® has not been clinically tested for its ability to reduce catheter related blood stream infections (CR-BSI).
Image /page/4/Picture/13 description: The image shows the logo for HemCon Europe. The logo consists of a symbol that looks like two overlapping circles on the left, followed by the text "HemCon" in a simple, sans-serif font. To the right of "HemCon", there is a vertical line, and then the word "EUROPE" in smaller, uppercase letters.
Page 1 of 5
5
Hem Con Medical Technologies Europe Ltd., 6 Courtyard Business Centre, Orchard Lane, Blackrock, Co. Dublin, Ireland
TEL: +353 (0) 1 2064727
FAX: +1 (503) 245-1326 EMAIL: info@hemcon.com
| Organism | Gram Stain | 24 Hr Log
Reduction | 7 Day Log
Reduction |
|-----------------------------------|------------|------------------------|------------------------|
| Staphylococcus aureus (MRSA) | + | >4.0 | >4.0 |
| Staphylococcus epidermidis (MRSE) | + | >4.0 | >4.0 |
| Enterococcus faecium (VRE) | + | >4.0 | >4.0 |
| Pseudomonas aeruginosa | | >4.0 | >4.0 |
| Acinetobacter baumanii | | >4.0 | >4.0 |
| Klebsiella pneumoniae | | >4 0 | >4.0 |
| Escherichia coli | - | >4.0 | >4.0 |
| Candida albicans | N/A | >4.0 | >4.0 |
| Aspergillus niger | NIA | >4.0 | >4.0 |
Table 1: Antimicrobial Efficacy of GuardlVa® assessed using Log Reduction of Organisms
Intended Use:
The HemCon GuardIVa® Antimicrobial Hemostatic IV Dressing is intended for use as a hydrophilic wound dressing to absorb exudate, cover and protect catheter sites. Common applications include IV catheters, other intravenous catheters and percutaneous devices. It is also indicated for control of surface bleeding from percutaneous catheters and vascular access sites.
Indications for Use (Rx):
The HemCon GuardIVa® Antimicrobial Hemostatic IV Dressing is intended for use as a hydrophilic wound dressing to absorb exudate, cover and protect catheter sites. Common applications include IV catheters, other intravenous catheters and percutaneous devices. It is also indicated for control of surface bleeding from percutaneous catheters and vascular access sites.
Technological Characteristics:
The version of GuardIVa® Antimicrobial Hemostatic IV Dressing that is the subject of this notification is technologically identical to the currently marketed GuardIVa® dressing originally cleared in K093729. The proposed changes to the product information are based on additional performance testing completed by HemCon and do not affect the fundamental scientific technological characteristics of the product.
KI21+88
Page 2 of 5
6
Hem Con Medical Technologies Europe Ltd., 6 Courtyard Business Centre, Orchard Lane, Blackrock, Co. Dublin, freland
FAX: +1 (503) 245-1326 EMAIL: info@hemcon.com TEL: +353 (0) 1 2064727
Summary of Performance Data:
Biocompatibility
Biocompatibility has been demonstrated per ISO 10993. Categorization of the device by nature of body contact deduces the GuardIVa® Antimicrobial Hemostatic IV Dressing is a surfacecontacting device that contacts breached or compromised surfaces. The duration of contact may be prolonged at more than 24 hours, but no more than 30 days. Cytotoxicity, irritation and sensitization testing was performed by contract testing laboratories under GLP conditions per standard protocols.
In Vivo Efficacy - Dermal Wound Healing Studies
Two independent in vivo dermal wound healing studies in rats were performed by contract testing laboratories under GLP conditions to demonstrate that the CHG in GuardlVa® does not adversely affect the rate of wound healing compared to un-treated wounds. Wounds treated with GuardIVa® healed at a rate comparable to untreated wounds with no visible signs of erythema and with an edema response comparable to that of un-treated wounds. Another commercially available CHG containing sponge dressing was used as a control and it did have a pronounced adverse effect on healing and edema.
In Vivo Efficacy - Hemostatic Properties of GuardIVa®
The haemostatic efficacy of GuardIVa® Antimicrobial Hemostatic IV Dressing was tested in comparison to standard gauze dressing in a rabbit ear model. The time to hemostasis was significantly reduced in wounds treated with GuardIVa® (48 s) compared to standard gauze (113 s). Furthermore, up to seven times less blood loss was observed for wounds treated with GuardIVa® (0.17 g) compared with standard gauze (1.30 g).
In Vivo Efficacy - Suppression of Skin Flora Re-growth in Healthy Volunteers
A study, conducted independently by the Centre for Laboratory Activities in Public Health Protection and Promotion, National Reference Laboratory for Disinfection and Sterilization, National Institute of Health, Prague, Czech Republic, on healthy human volunteers, demonstrated the ability of Guard|Va® to suppress skin flora re-growth for up to 10 days, maintaining skin flora at a level equivalent to that observed immediately following preoperative skin preparation (70% isopropy) alcohol solution).
HemCon EUROPE
K12 1485
Page 3 of 5
7
HemCon Medical Technologies Europe Ltd., 6 Courtyard Business Centre, Orchard Lane, Blackrock, Co. Dublin, Ireland
TEL: +353 (0) 1 2064727 FAX: +1 (503) 245-1326 EMAIL: info@hemcon.com
Sustained Antimicrobial Efficacy - 7 Day Log Reduction Values.
The sustained antimicrobial efficacy of GuardIVa® Antimicrobial Hemostatic IV Dressing, for up to 7 days, was demonstrated in vitro using a modified version of the AATCC Test Method 100-2004 "Assessment of Antibacterial Finishes on Textiles". GuardIVa® dressings were tested in triplicate against seven [7] bacterial strains, S. aureus (MRSA), S. epidermidis (MRSE), E. faecium (VRE), P. aeruginosa, A. baumanii, K. pneumoniae and E. coli, the diploid yeast C. albicans and the fungus A. niger. A greater than 4 log reduction in microbial count was observed for all test organisms.
Table 2: Organisms causing CRBSI and their prevalence
| Organism | Prevalence | GuardIVa Test Organism |
|---|---|---|
| Coagulase-negative | ||
| staphylococci | 31%† - 37%‡ | Staphylococcus epidermidis |
| Staphylococcus aureus | 20%† - 22%‡ | Staphylococcus aureus (MRSA) |
| Enteric Gram negative bacilli | 11%† - 12.4%‡ | Escherichia coli, Klebsiella pneumoniae |
| Yeast (Candida species) | 9%† - 9.3%‡ | Candida albicans |
| Pseudomonas | 5.5%‡ | Pseudomonas aeruginosa |
| Enterococci and Streptococci | 4.9%‡ - 9%† | Enterococcus faecium, |
| Other | 8.9%‡ - 20%† | Acinetobacter baumanii |
† Data from Abad & Safdar (2011) #Data from Fletcher (2005)
Antimicrobial Efficacy - Zone of Inhibition Measurements
Kirby-Bauer Zone of (nhibition (Zol) measurements were used to demonstrate the bactericidal or bacteriostatic properties of GuardIVa® Antimicrobial Hemostatic IV Dressing aqainst a range of micro-organisms over a 7 day period (See Table 3). Individual test articles were placed onto agar plates and incubated for 24 hr at 35 - 37°C. The area under the test articles was swabbed and the swab was transferred onto sterile agar plates. The test articles were then placed on a freshly inoculated agar plates and the procedure repeated for 7 days. Growth from the swabs taken from the test articles indicated bacteriostatic action (slowed growth over 7 days) of the CHG in GuardlVa®, while no growth over 7 days indicated bactericidal action. GuardIVa® Antimicrobial Hemostatic IV Dressing was shown to be bactericidal against five of the test organisms (MRSA, MRSE, VRE, E.coli and K. pneumoniae) and bacteriostatic against the other three organisms (P. aeruginosa, A. baumanii and C. albicans).
Table 3: Bactericidal and Bacteriostatic properties of GuardIVa® assessed using Kirby-Bauer Zone of Inhibition Measurements ,
Organism
Staphylococcus aureus (MRSA) Staphylococcus epidermidis (MRSE) Enterococcus faecium (VRE) Escherichia coli
Bactericidal Bactericidal Bactericidal Bactericidal
Image /page/7/Picture/13 description: The image shows the logo for HemCon Europe. The logo consists of a stylized symbol on the left, followed by the text "HemCon" in a simple, sans-serif font. A vertical dashed line separates "HemCon" from the word "EUROPE" on the right. The overall design is clean and professional.
K12/485
Page 4 of 5
8
Hem Con Medical Technologies Europe Ltd., 6 Courtyard Business Centre, Orchard Lane, Blackrock, Co. Dublin, Ireland
FAX: +1 (503) 245-1326 EMAIL: info@hemcan.com TEL: +353 (0) 1 2064727
Organism
Pseudomonas aeruginosa Bacteriostatic Acinetobacter baumanii Bacteriostatic Klebsiella pneumoniae Bactericidal Candida albicans Bacteriostatic
Sterility
A sterility validation for GuardIVa® Antimicrobial Hemostatic IV Dressing was completed following ISO 11137:2006 requirements to demonstrate a 10° SAL using the VDma25 method.
Conclusion:
GuardIVa® Antimicrobial Hemostatic IV Dressing is technologically identical to the predicate device. The conclusion drawn from the technological characteristics and performance data is that the GuardIVa® Antimicrobial Hemostatic IV Dressing is as safe and effective as the predicate device.
Image /page/8/Picture/8 description: The image shows the logo for HemCon Europe. The logo consists of a stylized infinity symbol to the left of the word "HemCon", which is written in a thin, sans-serif font. To the right of "HemCon" is a vertical line, followed by the word "EUROPE" in a smaller, sans-serif font.
K121485
Page 5 of 5